2. Others
  3. Isotope-Labeled Compounds
  4. 1219332-91-8

1219332-91-8

rac-Lenalidomide-<sup>13</sup>C<sub>5</sub> Chemical Structure

1219332-91-8

Chemical Structure

  • rac-Lenalidomide-13C5
  • Synonym(s): CC-5013-13C5
  • CAS No: 1219332-91-8
    Formula: C813C5H13N3O3
    Molecular Weight: 264.22
  • InChIKey: GOTYRUGSSMKFNF-GSUYAWNGSA-N
  • SMILES: O=[13C](N1)[13CH2][13CH2][13CH](N2CC3=C(C=CC=C3C2=O)N)[13C]1=O

Biological Activity: rac Lenalidomide-13C5 is a 13C-labeled rac Lenalidomide[1].

Cat. No. Product Name Purity Description
HY-W777286 rac-Lenalidomide-13C5 rac Lenalidomide-13C5 is a 13C-labeled rac Lenalidomide.
HY-A0003S2 Lenalidomide-13C5,15N Lenalidomide-13C5,15N is 15N and 13C labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
HY-A0003S Lenalidomide-d5 99.32% Lenalidomide-d5 is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
HY-A0003S3 Lenalidomide-d4 Lenalidomide-d4 (CC-5013-d4) is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
HY-A0003 Lenalidomide 99.95% Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
HY-A0003R Lenalidomide (Standard) ≥98% Lenalidomide (Standard) is the analytical standard of Lenalidomide. This product is intended for research and analytical applications. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.

References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]

Keywords:

rac-Lenalidomide-13C5Lenalidomide-13C5,15NLenalidomide-d5Lenalidomide-d4LenalidomideLenalidomide (Standard)